Quality, Production & Engineering Design Review, Proposed Engineering Solution Documentation and Validation.
GAMP Group provides an exceptionally skilled team of Quality ,Production ,Architects and Engineers to perfect your New EUGMP USFDA PICS WHO Based New Project including process, mechanical, HVAC, electrical, automation, and validation specialists in the fields of pharmaceutical, medical device ,biotech & food processing facilities.
Definition of best working practices
Technology fit for purpose
Optimization of capital investment & operating costs
Assured product quality while achieving optimal manufacturing efficiency
Compliance with international GMP & industrial safety standards
Environmental impact
When it comes to achieving EU GMP/US FDA compliance for your pharmaceutical production facility, you cannot afford to take risks.
GAMP Group is fast becoming the first choice EU GMP /US FDA compliance partner for manufacturers in the Asia/Europe/USA region.
Why? Because GAMP Group offers comprehensive in-house EU GMP /US FDA compliance services that will ensure a well-planned pathway towards EU market access.
Phase 1: EU GMP reviews, gap analysis, remediation
Phase 2: GMP training
Phase 3: EU GMP audit preparation
Phase 4: EU GMP pre-inspection audit by EU GMP partner
Phase 5: Final liaison with EU authorities
Our experienced consultants will train and lead your team towards successful EU GMP certification by creating a GMP culture and mindset that will leave the auditors in no doubt of your readiness to comply with EU GMP requirements.
Our structured approach and rigorous GMP reviews and Gap analysis will serve to align your facility documentation and processes with EU GMP regulations and guidelines prior to the arrival of the auditors.
Furthermore, our European-based third-party EU GMP pre-inspection auditor will provide a thorough assessment of the facility’s readiness prior to inviting the EU regulators for the audit.
We assist you to make critical decisions on your New EUGMP USFDA PICS WHO Based New Project viability by determining the financial outlay (CAPEX and OPEX), evaluating potential and current market trends, risk assessments, sales forecasts, and competitor analysis.
In this phase, a site investigation will be conducted jointly with you to gather relevant information required to design the building areas, production space, and logistics movement, do the infrastructure planning and optimization for future expansion, as well as to meet regulatory compliance both locally and internationally.
With all these elements taken into consideration, visuals of the new facilities will be developed and presented to you.
Study defining the purpose of a New EUGMP USFDA PICS WHO Based New Project, the location and cost assessment. The development stage defining the type, utilization and location of machines, processes, and plant services within a factory to meet output, quality, safety, and regulatory demands; provides the operational philosophy, the layout and cost estimate.
Production building layouts will be developed based on the production equipment and operational requirements, to facilitate smooth production flow and maintenance works.
Layouts will also be developed for laboratories, warehouses, offices, and other required support areas.
During this conceptual design phase, the initial New EUGMP USFDA PICS WHO Based New Project investment cost estimates will be established for our clients.
The basic design phase will advance the design across the various engineering disciplines, including process, architectural, structural and civil, utilities, HVAC, electrical, and fire. The major objective of this phase is ensuring all major building elements, equipment, and systems are defined and accounted for in the overall design, and that everything is laid out in an optimal fashion, maximizing operational efficiency and minimizing costs.
The basic design will provide an approved set of drawings and documents defining the basis of design for the facility, allowing the New EUGMP USFDA PICS WHO Based New Project to subsequently be fully engineered with changes mitigated. Capital investment costs will be further refined to provide more accurate New EUGMP USFDA PICS WHO Based New Project cost estimates.
Our detailed design package provides over 500 items – including all the drawings, specifications and documentation needed to progress the New EUGMP USFDA PICS WHO Based New Project into the implementation phase. As part of this engineering phase we produce a comprehensive package of technical information that will be used as a basis upon which to purchase, build, install, commission, validate and qualify your facilities and equipment.